Deficiency of one or more anterior pituitary hormones may follow treatment with external irradiation when the hypothalamic-pituitary axis falls within the fields of irradiation. Hypopituitarism occurs in patients who receive radiation therapy for pituitary tumours, nasopharyngeal cancer and primary brain tumours, as well as in children who undergo prophylactic cranial irradiation for acute lymphoblastic leukaemia, or total body irradiation for a variety of tumours and other diseases. The degree of pituitary hormonal deficit is related to the radiation dose received by the hypothalamic-pituitary axis. Thus, after lower radiation doses isolated growth hormone deficiency ensues, whilst higher doses may produce hypopituitarism. The timing of onset of the radiation-induced pituitary hormone deficit is also dose-dependent. The main site of radiation damage is the hypothalamus rather than the pituitary, although the latter may be affected directly.

Keywords:
Cranial irradiation, Growth hormone deficiency
1.
Clayton PE, Shalet SM: Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991;118(2):226–228.
2.
Shalet SM, Price DA, Beardwell CG, Jones PH, Pearson D: Normal growth despite abnormalities of growth hormone secretion in children treated for acute leukemia. J Pediatr 1979;94(5):719–722.
3.
Costin G: Effects of low-dose cranial radiation on growth hormone secretory dynamics and hypothalamic-pituitary function. Am J Dis Child 1988;142(8):847–852.
4.
Shalet SM, Beardwell CG, Jones PH, Pearson D: Growth hormone deficiency after treatment of acute leukaemia in children. Arch Dis Child 1976;51(7):489–493.
5.
Kirk JA, Raghupathy P, Stevens MM, Cowell CT, Menser MA, Bergin M, Tink A, Vines RH, Silink M: Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia. Lancet 1987;1(8526):190–193.
6.
Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM: Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998;48(6):777–783.
7.
Ogilvy-Stuart AL, Clark DJ, Wallace WH, Gibson BE, Stevens RF, Shalet SM, Donaldson MD: Endocrine deficit after fractionated total body irradiation. Arch Dis Child 1992;67(9):1107–1110.
8.
Duffner PK, Cohen ME, Voorhess ML, MacGillivray MH, Brecher ML, Panahon A, Gilani BB: Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer 1985;56(9):2189–2193.
9.
Shalet SM, Beardwell CG, Morris-Jones PH, Pearson D: Pituitary function after treatment of intracranial tumours in children. Lancet 1975;2(7925):104–107.
10.
Chen MS, Lin FJ, Huang MJ, Wang PW, Tang S, Leung WM, Leung W: Prospective hormone study of hypothalamic-pituitary function in patients with nasopharyngeal carcinoma after high dose irradiation. Jpn J Clin Oncol 1989;19(3):265–270.
11.
Littley MD, Shalet SM, Morgenstern GR, Deakin DP: Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med 1991;78(287):265–274.
12.
Brauner R, Czernichow P, Rappaport R: Greater susceptibility to hypothalamopituitary irradiation in younger children with acute lymphoblastic leukemia. J Pediatr 1986;108(2):332.
13.
Samaan NA, Schultz PN, Yang KP, Vassilopoulou-Sellin R, Maor MH, Cangir A, Goepfert H: Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987;109(3):364–372.
14.
Chrousos GP, Poplack D, Brown T, O’Neill D, Schwade J, Bercu BB: Effects of cranial radiation on hypothalamic-adenohypophyseal function: abnormal growth hormone secretory dynamics. J Clin Endocrinol Metab 1982;54(6):1135–1139.
15.
Spoudeas HA, Hindmarsh PC, Matthews DR, Brook CG: Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumours: a prospective study. J Endocrinol 1996;150(2):329–342.
16.
Blatt J, Bercu BB, Gillin JC, Mendelson WB, Poplack DG: Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr 1984;104(2):182–186.
17.
Bercu BB, Diamond FB Jr: Growth hormone neurosecretory dysfunction. Clin Endocrinol Metab 1986;15(3):537–590.
18.
Albertsson-Wikland K, Lannering B, Marky I, Mellander L, Wannholt U: A longitudinal study on growth and spontaneous growth hormone (GH) secretion in children with irradiated brain tumors. Acta Paediatr Scand 1987;76(6):966–973.
19.
Brauner R, Rappaport R, Prevot C, Czernichow P, Zucker JM, Bataini P, Lemerle J, Sarrazin D, Guyda HJ: A prospective study of the development of growth hormone deficiency in children given cranial irradiation, and its relation to statural growth. J Clin Endocrinol Metab 1989;68(2):346–351.
20.
Moell C, Garwicz S, Westgren U, Wiebe T, Albertsson-Wikland K: Suppressed spontaneous secretion of growth hormone in girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1989;64(2):252–258.
21.
Moell C, Garwicz S, Westgren U, Wiebe T: Disturbed pubertal growth in girls treated for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1987;4(1):1–5.
22.
Crowne EC, Moore C, Wallace WH, Ogilvy-Stuart AL, Addison GM, Morris-Jones PH, Shalet SM: A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation. Clin Endocrinol (Oxf) 1992;36(1):59–68.
23.
Lannering B, Rosberg S, Marky I, Moell C, Albertsson-Wikland K: Reduced growth hormone secretion with maintained periodicity following cranial irradiation in children with acute lymphoblastic leukaemia. Clin Endocrinol (Oxf) 1995;42(2):153–159.
24.
Stubberfield TG, Byrne GC, Jones TW: Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 1995;17(2):167–171.
25.
Shalet SM, Toogood AA, Rahim A, Brennan BMD: The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998;19(2):203–223.
26.
Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KK: Diagnosis of GH deficiency in adults; in Jørgensen JOL (ed): Growth Hormone in Adults. Cambridge, UK, Cambridge University Press, 1996, pp 168–185.
27.
Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83(2):379–381.
28.
Lissett CA, Saleem S, Rahim A, Brennan BM, Shalet SM: The impact of irradiation on growth hormone responsiveness to provocative agents is stimulus dependent: results in 161 individuals with radiation damage to the somatotropic axis. J Clin Endocrinol Metab 2001;86(2):663–668.
29.
Dickinson WP, Berry DH, Dickinson L, Irvin M, Schedewie H, Fiser RH, Elders MJ: Differential effects of cranial radiation on growth hormone response to arginine and insulin infusion. J Pediatr 1978;92(5):754–757.
30.
Tillmann V, Buckler JM, Kibirige MS, Price DA, Shalet SM, Wales JK, Addison MG, Gill MS, Whatmore AJ, Clayton PE: Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997;82(2):531–535.
31.
Sklar C, Sarafoglou K, Whittam E: Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol (Copenh) 1993;129(6):511–515.
32.
Nivot S, Benelli C, Clot JP, Saucet C, Adan L, Souberbielle JC, Zucker JM, Rappaport R, Brauner R: Nonparallel changes of growth hormone (GH) and insulin-like growth factor-I, insulin-like growth factor binding protein-3, and GH-binding protein, after craniospinal irradiation and chemotherapy. J Clin Endocrinol Metab 1994;78(3):597–601.
33.
Tillmann V, Shalet SM, Price DA, Wales JK, Pennells L, Soden J, Gill MS, Whatmore AJ, Clayton PE: Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation. Horm Res 1998;50(2):71–77.
34.
Achermann JC, Hindmarsh PC, Brook CG: The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol (Oxf) 1998;49(5):639–645.
35.
Cicognani A, Cacciari E, Pession A, Pasini A, De Iasio R, Gennari M, Alvisi P, Pirazzoli P: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) concentrations compared to stimulated growth hormone (GH) in the evaluation of children treated for malignancy. J Pediatr Endocrinol Metab 1999;12(5):629–638.
36.
Adan L, Trivin C, Sainte-Rose C, Zucker JM, Hartmann O, Brauner R: GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults. J Clin Endocrinol Metab 2001;86(11):5245–5251.
37.
Adan L, Souberbielle JC, Blanche S, Leverger G, Schaison G, Brauner R: Adult height after cranial irradiation with 24 Gy: factors and markers of height loss. Acta Paediatr 1996;85(9):1096–1101.
38.
Melin AE, Adan L, Leverger G, Souberbielle JC, Schaison G, Brauner R: Growth hormone secretion, puberty and adult height after cranial irradiation with 18 Gy for leukaemia. Eur J Pediatr 1998;157(9):703–707.
39.
Giorgiani G, Bozzola M, Locatelli F, Picco P, Zecca M, Cisternino M, Dallorso S, Bonetti F, Dini G, Borrone C: Regazzi MB, DeStefanor P, Severi, F: Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995;86(2):825–831.
40.
Brauner R, Adan L, Souberbielle JC, Esperou H, Michon J, Devergie A, Gluckman E, Zucker JM: Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation. J Pediatr 1997;130(5):785–792.
41.
Sanders JE, Buckner CD, Sullivan KM, Doney K, Appelbaum F, Witherspoon R, Storb R, Thomas ED: Growth and development in children after bone marrow transplantation. Horm Res 1988;30:92–97.
42.
Papadimitriou A, Urena M, Hamill G, Stanhope R, Leiper AD: Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation. Arch Dis Child 1991;66(6):689–692.
43.
Borgstrom B, Bolme P: Growth and growth hormone in children after bone marrow transplantation. Horm Res 1988;30(2–3):98–100.
44.
Olshan JS, Willi SM, Gruccio D, Moshang T Jr: Growth hormone function and treatment following bone marrow transplant for neuroblastoma. Bone Marrow Transplant 1993;12(4):381–385.
45.
Hovi L, Saarinen UM, Siimes MA: Growth failure in children after total body irradiation preparative for bone marrow transplantation. Bone Marrow Transplant 1991;8(suppl 1):10–13.
46.
Brauner R, Fontoura M, Zucker JM, Devergie A, Souberbielle JC, Prevot-Saucet C, Michon J, Gluckman E, Griscelli C, Fischer A, Rappaport R: Growth and growth hormone secretion after bone marrow transplantation. Arch Dis Child 1993;68(4):458–463.
47.
Thomas BC, Stanhope R, Plowman PN, Leiper AD: Endocrine function following single fraction and fractionated total body irradiation for bone marrow transplantation in childhood. Acta Endocrinol (Copenh) 1993;128(6):508–512.
48.
Huma Z, Boulad F, Black P, Heller G, Sklar C: Growth in children after bone marrow transplantation for acute leukemia. Blood 1995;86(2):819–824.
49.
Clement-De Boers A, Oostdijk W, Van Weel-Sipman MH, Van den Broeck J, Wit JM, Vossen JM: Final height and hormonal function after bone marrow transplantation in children. J Pediatr 1996;129(4):544–550.
50.
Shalet SM, Beardwell CG, Aarons BM, Pearson D, Jones PH: Growth impairment in children treated for brain tumours. Arch Dis Child 1978;53(6):491–494.
51.
Brown IH, Lee TJ, Eden OB, Bullimore JA, Savage DC: Growth and endocrine function after treatment for medulloblastoma. Arch Dis Child 1983;58:722–727.
52.
Darendeliler F, Livesey EA, Hindmarsh PC, Brook CG: Growth and growth hormone secretion in children following treatment of brain tumours with radiotherapy. Acta Paediatr Scand 1990;79(10):950–956.
53.
Clarson CL, Del Maestro RF: Growth failure after treatment of pediatric brain tumors. Pediatrics 1999;103(3):E37.
54.
Shalet SM, Whitehead E, Chapman AJ, Beardwell CG: The effects of growth hormone therapy in children with radiation-induced growth hormone deficiency. Acta Paediatr Scand 1981;70(1):81–86.
55.
Lannering B, Marky I, Mellander L, Albertsson-Wikland K: Growth hormone secretion and response to growth hormone therapy after treatment for brain tumour. Acta Paediatr Scand Suppl 1988;343:146–151.
56.
Ilveskoski I, Saarinen UM, Wiklund T, Sipila I, Makipernaa A, Perkkio M, Lanning M, Salmi TT, Pihko H: Growth impairment and growth hormone therapy in children treated for malignant brain tumours. Eur J Pediatr 1997;156(10):764–769.
57.
Clayton PE, Shalet SM, Price DA: Growth response to growth hormone therapy following cranial irradiation. Eur J Pediatr 1988;147(6):593–596.
58.
Clayton PE, Shalet SM, Price DA: Growth response to growth hormone therapy following craniospinal irradiation. Eur J Pediatr 1988;147(6):597–601.
59.
Oberfield SE, Allen JC, Pollack J, New MI, Levine LS: Long-term endocrine sequelae after treatment of medulloblastoma: prospective study of growth and thyroid function. J Pediatr 1986;108(2):219–223.
60.
Shalet SM, Gibson B, Swindell R, Pearson D: Effect of spinal irradiation on growth. Arch Dis Child 1987;62(5):461–464.
61.
Olshan JS, Gubernick J, Packer RJ, D’Angio GJ, Goldwein JW, Willi SM, Moshang T Jr: The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70(7):2013–2017.
62.
Ogilvy-Stuart AL, Shalet SM: Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995;73(2):141–146.
63.
Romshe CA, Zipf WB, Miser A, Miser J, Sotos JF, Newton WA: Evaluation of growth hormone release and human growth hormone treatment in children with cranial irradiation-associated short stature. J Pediatr 1984;104(2):177–181.
64.
Sulmont V, Brauner R, Fontoura M, Rappaport R: Response to growth hormone treatment and final height after cranial or craniospinal irradiation. Acta Paediatr Scand 1990;79(5):542–549.
65.
Vassilopoulou S, Klein MJ, Moore BD 3rd, Reid HL, Ater J, Zietz HA: Efficacy of growth hormone replacement therapy in children with organic growth hormone deficiency after cranial irradiation. Horm Res 1995;43(5):188–193.
66.
Bundak R, Hindmarsh PC, Brook CG: Body segments and growth hormone. Arch Dis Child 1988;63(7):839–840.
67.
Didi M, Brennan BMD, Shalet SM: Growth hormone replacement in children treated for leukemia in childhood. Horm Res 1997;48(suppl 2):65.
68.
Clayton PE, Shalet SM, Gattamaneni HR, Price DA: Does growth hormone cause relapse of brain tumours? Lancet 1987;1(8535):711–713.
69.
Clayton PE, Cowell CT: Safety issues in children and adolescents during growth hormone therapy – a review. Growth Horm IGF Res 2000;10(6):306–317.
70.
Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG, Hindmarsh PC, Shalet SM: Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85(12):4444–4449.
71.
Ogilvy-Stuart AL, Ryder WD, Gattamaneni HR, Clayton PE, Shalet SM: Growth hormone and tumour recurrence. Br Med J 1992;304(6842):1601–1605.
72.
Wilton P, on behalf of the International Board of the Kabi Pharmacia International Growth Study: Safety of growth hormone (GH) – value of a large data base. Clin Pediatr Endocrinol 1994;3(suppl 5):61–71.
73.
Maneatis T, Baptista J, Connelly K, Blethen S: Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000;13(suppl 2):1035–1044.
74.
Shalet SM, Brennan BM, Reddingius RE: Growth hormone therapy and malignancy. Horm Res 1997;48(suppl 4):29–32.
75.
Taha DR, Bastian W, Castells S: Growth hormone replacement therapy in children with leukemia in remission. Clin Pediatr (Phil) 2001;40(8):441–445.
76.
Leiper A: Growth hormone deficiency in children treated for leukemia. Acta Paediatr Scand 1995;84(suppl 411):41–44.
77.
Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J, for the Genentech, Inc, Cooperative Study Group: High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 2000;85(10):3653–3660.
78.
Stanhope R, Uruena M, Hindmarsh P, Leiper AD, Brook CG: Management of growth hormone deficiency through puberty. Acta Paediatr Scand Suppl 1991;372:47–52; discussion 53.
79.
Cassorla F, Mericq V, Eggers M, Avila A, Garcia C, Fuentes A, Rose SR, Cutler GB Jr: Effects of luteinizing hormone-releasing hormone analog-induced pubertal delay in growth hormone (GH)-deficient children treated with GH: preliminary results. J Clin Endocrinol Metab 1997;82(12):3989–3992.
80.
Cara JF, Kreiter ML, Rosenfield RL: Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone. J Pediatr 1992;120(5):709–715.
81.
Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F: Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000;85(2):569–573.
82.
Adan L, Sainte-Rose C, Souberbielle JC, Zucker JM, Kalifa C, Brauner R: Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation. Med Pediatr Oncol 2000;34(1):14–19.
83.
de Boer H, Blok GJ, van der Veen EA: Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995;16(1):63–86.
84.
Carroll PV, Christ ER, Bengtsson B-Å, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorne M, for the Growth Hormone Research Society Scientific Committee: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998;83(2):382–395.
85.
Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Shalet SM: Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol (Oxf) 1999;50(6):749–757.
86.
Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM: High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127(1):63–67.
87.
Sklar CA, Mertens AC, Walter A, Mitchell D, Nesbit ME, O’Leary M, Hutchinson R, Meadows AT, Robison LL: Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 2000;35(2):91–95.
88.
Brennan BM, Rahim A, Adams JA, Eden OB, Shalet SM: Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 1999;79(11–12):1859–1863.
89.
Talvensaari KK, Lanning M, Tapanainen P, Knip M: Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 1996;81(8):3051–3055.
90.
Herold AH, Roetzheim RG: Cancer survivors. Primary Care 1992;19(4):779–791.
91.
Murray RD, Darzy KH, Gleeson HK, Shalet SM: GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab 2002;87(1):129–135.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.